
Claims

1. A compound, wherein the compound is represented by Formula I or is a pharmaceutically acceptable salt thereof:



(I)

wherein:

R is hydrogen;

R^1 is hydrogen or methoxy;

R^2 is selected from methyl, 2-propenyl, *cis*-2-butenyl, *trans*-2-butenyl, 2- methyl-2-propenyl and *i*-propyl;

R^3 is hydrogen or methoxy;

R^4 is selected from hydroxyl, halogen, methoxy, ethynyl, ethyl, and methyl substituted with hydroxyl;

R^5 is hydrogen; and

R^6 is hydrogen,

with the provisos that:

(a) when R^1 is hydrogen and R^2 is methyl, then R^3 and R^4 are not both methoxy and




(b) when R^1 is hydrogen, R^2 is methyl, R^3 is hydrogen, and R^4 is halo, then R^4 is bromo.




2. The compound according to claim 1, wherein R^2 is methyl.




3. The compound according to claim 1, wherein R^4 is methoxy or halogen.



4. The compound according to claim 1, wherein R^4 is bromo.

5. The compound according to claim 1, wherein the compound is selected from:


;

;

;



;

;

;


;

;

;


;



or is a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1, wherein the compound is




or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1, wherein the compound is




or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1, wherein the compound is




or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 1, wherein the compound is




or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 1, wherein the compound is




or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1, wherein the compound is




or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound according to any one of claims 1-13 and a pharmaceutically acceptable carrier.

15. The pharmaceutical composition according to claim 14, wherein the composition is suitable for oral administration.

16. The pharmaceutical composition according to claim 14, wherein the composition is suitable for subcutaneous injection.

17. The pharmaceutical composition according to claim 14, wherein the composition is suitable for intravenous injection.

18. The pharmaceutical composition according to claim 14, wherein the composition is suitable for administration to nasal membranes.

19. A parenteral injection kit for reconstitution comprising a vial comprising a lyophilized compound according to any one of claims 1-13.

20. A compound according to any one of claims 1-13 for use as a medicament.

21. A compound according to any one of claims 1-13 for use in treating a central nervous system (CNS) disease or disorder in a subject.

22. The compound for use according to claim 21, wherein the CNS disease or disorder is alleviated by 5-HT_{2A} agonism.

23. The compound for use according to claim 21, wherein the disease or disorder is selected from generalized anxiety disorder (GAD), depression, major depressive disorder (MDD), postpartum depression, drug-resistant depression, alcoholism, tobacco addiction, cocaine addiction, opioid dependence, inflammation, cluster headache, gambling disorder, an eating disorder, chronic pain, chronic fatigue, obsessive compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).

24. The compound for use according to claim 21, wherein the disease or disorder is selected from generalized anxiety disorder (GAD), depression, major depressive disorder (MDD), postpartum depression, drug-resistant depression, cluster headache, obsessive compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).

25. The compound for use according to claim 21, wherein the subject receives an antidepressant drug.

26. The compound for use according to claim 21, wherein the subject receives psychotherapy.

27. Use of a compound according to any one of claims 1-13 in the manufacture of a medicament for treating a central nervous system (CNS) disease or disorder in a subject.

28. The use according to claim 27, wherein the CNS disease or disorder is alleviated by 5-HT_{2A} agonism.

29. The use according to claim 27, wherein the disease or disorder is selected from generalized anxiety disorder (GAD), depression, major depressive disorder (MDD), postpartum depression, drug-resistant depression, alcoholism, tobacco addiction, cocaine addiction, opioid dependence, inflammation, cluster headache, gambling disorder, an eating disorder, chronic pain, chronic fatigue, obsessive compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).

30. The use according to claim 27, wherein the disease or disorder is selected from generalized anxiety disorder (GAD), depression, major depressive disorder (MDD), postpartum depression, drug-resistant depression, cluster headache, obsessive compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).

31. The use according to claim 27, wherein the subject receives an antidepressant drug.

32. The use according to claim 27, wherein the subject receives psychotherapy.